Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Active not recruiting 5Recruiting 3Terminated 1Enrolling by invitation 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 1NIH 1

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Genitourinary 2Tumor-Agnostic 1Thoracic 1Dermatologic 1

Conditions

Urinary Bladder Neoplasms 1Thymoma 1Skin Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasm Metastasis 1Carcinoma, Transitional Cell 1

Interventions

Specimen Handling 111Magnetic Resonance Spectroscopy 88Carboplatin 58pembrolizumab 57Biopsy 56Cisplatin 51Nivolumab 46Paclitaxel 39Radiotherapy 38Cyclophosphamide 38Gemcitabine 33Dexamethasone 31Radiation 30Bevacizumab 30atezolizumab 27Pemetrexed 27Etoposide 27olaparib 24Lenalidomide 24Doxorubicin 23X-Rays 22Vincristine 22Prednisone 22Leucovorin 22Immunoglobulin G 22Docetaxel 22Disulfides 22venetoclax 21durvalumab 21Rituximab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × avelumab × 30 days × Clear all
NCT03944941 2026-06-02

Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Active not recruiting
60 enrolled 19 charts
Dermatologic

Skin Neoplasms

NCT03076554 2026-05-29

A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
56 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Thymoma

NCT05396833 2026-05-28

Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)

EMD Serono

Phase 1 Active not recruiting
120 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT06412848 2026-05-28

JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Active not recruiting
360 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT06225596 2026-05-27

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

BicycleTx Limited

Phase 2 Active not recruiting
375 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡